title: CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.
abstract: Raloxifene was approved in 2007 by the FDA for the chemoprevention of breast cancer in postmenopausal women at high risk for invasive breast cancer. Approval was based in part on the improved safety profile for raloxifene relative to the standard treatment of tamoxifen. However, recent studies have demonstrated the ability of raloxifene to form reactive intermediates and act as a mechanism-based inhibitor of cytochrome P450 3A4 (CYP3A4) by forming adducts with the apoprotein. However, previous studies could not differentiate between dehydrogenation to a diquinone methide and the more common oxygenation pathway to an arene oxide as the most likely intermediate to inactivate CYP3A4. In the current work, (18)O-incorporation studies were utilized to carefully elucidate CYP3A4-mediated oxygenation versus dehydrogenation of raloxifene. These studies established that 3'-hydroxyraloxifene is produced exclusively via CYP3A4-mediated oxygenation and provide convincing evidence for the mechanism of CYP3A4-mediated dehydrogenation of raloxifene to a reactive diquinone methide, while excluding the alternative arene oxide pathway. Furthermore, it was demonstrated that 7-hydroxyraloxifene, which was previously believed to be a typical O(2)-derived metabolite of CYP3A4, is in fact produced by a highly unusual hydrolysis pathway from a putative ester, formed by the conjugation of raloxifene diquinone methide with a carboxylic acid moiety of CYP3A4, or other proteins in the reconstituted system. These findings not only confirm CYP3A4-mediated dehydrogenation of raloxifene to a reactive diquinone methide but also suggest a novel route of raloxifene toxicity.
authors.affiliation: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA.
authors.forename: Chad D
authors.initials: CD
authors.lastname: Moore
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Reilly
authors.forename: Garold S
authors.initials: GS
authors.lastname: Yost
mesh_terms: D001059:Apoproteins / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D018890:Chemoprevention; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D004249:DNA Damage; D005260:Female; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013629:Tamoxifen / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001059:Apoproteins; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
references.citation: Drug Metab Dispos. 2002 Jun;30(6):694-700
references.pmid: 12019197
references.citation: Carcinogenesis. 1994 Oct;15(10):2087-94
references.pmid: 7955037
references.citation: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references.pmid: 9747868
references.citation: J Clin Oncol. 1993 Mar;11(3):485-90
references.pmid: 8383191
references.citation: Arch Biochem Biophys. 1998 Feb 15;350(2):223-32
references.pmid: 9473295
references.citation: Carcinogenesis. 1997 Oct;18(10):1949-54
references.pmid: 9364005
references.citation: J Med Chem. 1984 Aug;27(8):1057-66
references.pmid: 6431104
references.citation: Drugs. 2000 Aug;60(2):379-411
references.pmid: 10983739
references.citation: Chem Res Toxicol. 2007 Oct;20(10):1373-8
references.pmid: 17867646
references.citation: J Phys Chem B. 2009 Oct 1;113(39):13018-25
references.pmid: 19728720
references.citation: Cancer Res. 1992 Mar 1;52(5):1360-3
references.pmid: 1737398
references.citation: J Natl Cancer Inst. 1994 Apr 6;86(7):527-37
references.pmid: 8133536
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4151-9
references.pmid: 18757329
references.citation: Recent Results Cancer Res. 2009;181:113-9
references.pmid: 19213563
references.citation: Chem Res Toxicol. 2005 Feb;18(2):162-73
references.pmid: 15720120
references.citation: N Engl J Med. 1998 Nov 26;339(22):1609-18
references.pmid: 9828250
references.citation: J Natl Cancer Inst. 1996 Jun 19;88(12):832-4
references.pmid: 8637050
references.citation: Drug Metab Rev. 2004 May;36(2):199-218
references.pmid: 15237851
references.citation: Chem Res Toxicol. 2002 Jul;15(7):907-14
references.pmid: 12119000
references.citation: N Engl J Med. 1998 Oct 1;339(14):974-84
references.pmid: 9753714
references.citation: Chem Res Toxicol. 2005 Sep;18(9):1485-96
references.pmid: 16167842
references.citation: Chem Res Toxicol. 2007 Nov;20(11):1676-84
references.pmid: 17630709
references.citation: Carcinogenesis. 1999 Mar;20(3):471-7
references.pmid: 10190564
references.citation: Chem Res Toxicol. 1989 Sep-Oct;2(5):280-1
references.pmid: 2519818
references.citation: Biomed Environ Mass Spectrom. 1990 Apr;19(4):211-7
references.pmid: 2340358
references.citation: Chem Res Toxicol. 2007 Jun;20(6):954-64
references.pmid: 17497897
references.citation: Chem Res Toxicol. 2007 Dec;20(12):1778-86
references.pmid: 18001057
references.citation: J Natl Cancer Inst. 2005 Mar 2;97(5):375-84
references.pmid: 15741574
references.citation: Chem Res Toxicol. 2004 Jul;17(7):879-88
references.pmid: 15257612
references.citation: J Biol Chem. 1989 May 5;264(13):7584-9
references.pmid: 2708380
references.citation: Chem Res Toxicol. 2008 Sep;21(9):1814-22
references.pmid: 18690722
references.citation: Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60
references.pmid: 19105706
references.citation: Methods Enzymol. 2004;378:110-23
references.pmid: 15038960